CN118384160A - 用于控制和/或降低近视发展的药物组合物 - Google Patents

用于控制和/或降低近视发展的药物组合物 Download PDF

Info

Publication number
CN118384160A
CN118384160A CN202410507498.4A CN202410507498A CN118384160A CN 118384160 A CN118384160 A CN 118384160A CN 202410507498 A CN202410507498 A CN 202410507498A CN 118384160 A CN118384160 A CN 118384160A
Authority
CN
China
Prior art keywords
pharmaceutical composition
ophthalmic
eye
atropine
myopia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410507498.4A
Other languages
English (en)
Chinese (zh)
Inventor
米纳斯·希欧多尔·科罗内奥
莫尼卡·钟
P·R·桑卡里杜尔格
E·L·史密斯三世
阿曼迪普·考尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warbone Vision Research Center Co ltd
Original Assignee
Warbone Vision Research Center Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warbone Vision Research Center Co ltd filed Critical Warbone Vision Research Center Co ltd
Publication of CN118384160A publication Critical patent/CN118384160A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202410507498.4A 2017-11-03 2018-11-02 用于控制和/或降低近视发展的药物组合物 Pending CN118384160A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762581112P 2017-11-03 2017-11-03
US62/581,112 2017-11-03
CN201880085219.2A CN111787920A (zh) 2017-11-03 2018-11-02 用于控制和/或降低近视发展的药物组合物
PCT/AU2018/051187 WO2019084621A1 (en) 2017-11-03 2018-11-02 Pharmaceutical compositions for controlling and/or reducing the progression of myopia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880085219.2A Division CN111787920A (zh) 2017-11-03 2018-11-02 用于控制和/或降低近视发展的药物组合物

Publications (1)

Publication Number Publication Date
CN118384160A true CN118384160A (zh) 2024-07-26

Family

ID=66331107

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410507498.4A Pending CN118384160A (zh) 2017-11-03 2018-11-02 用于控制和/或降低近视发展的药物组合物
CN201880085219.2A Pending CN111787920A (zh) 2017-11-03 2018-11-02 用于控制和/或降低近视发展的药物组合物
CN202410507406.2A Pending CN118403054A (zh) 2017-11-03 2018-11-02 用于控制和/或降低近视发展的药物组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201880085219.2A Pending CN111787920A (zh) 2017-11-03 2018-11-02 用于控制和/或降低近视发展的药物组合物
CN202410507406.2A Pending CN118403054A (zh) 2017-11-03 2018-11-02 用于控制和/或降低近视发展的药物组合物

Country Status (10)

Country Link
US (1) US20200345633A1 (https=)
EP (1) EP3703691A4 (https=)
JP (2) JP2021501803A (https=)
KR (1) KR20200088824A (https=)
CN (3) CN118384160A (https=)
AU (1) AU2018359013A1 (https=)
CA (1) CA3081593A1 (https=)
SG (1) SG11202004005RA (https=)
TW (1) TW201932104A (https=)
WO (1) WO2019084621A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763280A1 (de) * 2019-07-11 2021-01-13 Carl Zeiss Vision International GmbH Bestimmung einer veränderung eines refraktionsfehlers eines auges
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN116785286B (zh) * 2020-10-10 2026-02-17 远大医学营养科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
US20240261291A1 (en) * 2021-06-11 2024-08-08 Brien Holden Vision Institute Limited Ophthalmic Compositions and/or Methods for Presbyopia, Mydriasis and/or Ocular Discomfort Management
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
CN119139472A (zh) * 2024-09-26 2024-12-17 温州医科大学附属眼视光医院 腺苷信号阻滞剂在制备治疗弱视和改善视觉可塑性的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG61430B1 (bg) * 1994-03-23 1997-08-29 Иван ХРИСТОВ антиастматично лекарствено средство
AU2100795A (en) * 1994-06-06 1996-01-04 Warner-Lambert Company Non-sedating allergy sinus medication
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
US6710051B1 (en) * 1997-01-06 2004-03-23 Klaus Trier Aps Screening method
US9034830B2 (en) * 2009-10-30 2015-05-19 Intratus, Inc. Methods and compositions for sustained delivery of drugs
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
JP5993620B2 (ja) * 2011-06-01 2016-09-14 ロート製薬株式会社 点眼剤
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition

Also Published As

Publication number Publication date
KR20200088824A (ko) 2020-07-23
CN111787920A (zh) 2020-10-16
CN118403054A (zh) 2024-07-30
AU2018359013A1 (en) 2020-05-21
US20200345633A1 (en) 2020-11-05
CA3081593A1 (en) 2019-05-09
WO2019084621A1 (en) 2019-05-09
TW201932104A (zh) 2019-08-16
EP3703691A4 (en) 2021-07-28
SG11202004005RA (en) 2020-05-28
JP2021501803A (ja) 2021-01-21
JP2023179418A (ja) 2023-12-19
EP3703691A1 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
US20250049761A1 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
JP7042274B2 (ja) 眼内炎症性眼疾患の治療のためのタクロリムスを含む組成物
CN118384160A (zh) 用于控制和/或降低近视发展的药物组合物
JP7795555B2 (ja) 近視を治療するための方法及び薬物組成物
JP2024506384A (ja) ロフルミラストの眼科的送達方法
CN115634226B (zh) 一种采用长春西汀治疗近视的方法
HK40039952A (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
HK40086794B (zh) 一种采用长春西汀治疗近视的方法
HK40086794A (zh) 一种采用长春西汀治疗近视的方法
HK40011588A (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
HK1198426B (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
NZ623037B2 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination